7 results
Ticagrelor, at steady state (i.e. after 30 days), will be associated to an improved endothelial function as compared to clopidogrel or prasugrel.
Primary Objectives:1. To compare the magnitude of baseline (or intrinsic) platelet reactivity between T2DM patients and healthy volunteers using multiple platelet function assays 2. To compare the magnitude of baseline (or intrinsic) platelet…
To evaluate safety of 3-months versus standard 12-months of DAPT
To determine if ticagrelor at treatment steady state will be associated to an improved microvascular function as compared to prasugrel in revascularized STEMI patients.
To assess the efficacy, safety and cost-effectiveness of the CYP2C19 genotype guided antiplatelet treatment strategy, using clopidogrel or prasugrel/ticagrelor.
To assess the safety, efficacy and net clinical benefit of clopidogrel versus the new antiplatelet drugs i.e. ticagrelor and prasugrel in patients older than 70 years.
To evaluate the efficacy of rVWF (vonicog alfa) prophylaxis based on the annualized bleeding rate (ABR) of spontaneous (not related to trauma) bleeding episodes in adult and pediatric / adolescent subjects (aged 12 to <18 years) during the…